Warren leads movement disorders preclinical research efforts in Biogen’s Neurodegeneration Research Unit. He is responsible for developing and driving a diverse preclinical portfolio of programs, to complement Biogen’s development efforts for their a-synuclein antibody, which is in Phase 2 trials, using multiple modalities, from antibodies and antisense oligonucleotides, in collaboration in Ionis, to gene therapy and small molecules, targeting mechanisms strongly supported by human genetics and pathology, to deliver novel disease-modifying therapeutics to patients. Warren has 22 years of industry experience, working for GlaxoSmithKline, Wyeth, Pfizer and now Biogen.
Co-PI (Core Leadership)
Warren Hirst, PhD
Biogen, Inc.
Warren leads movement disorders preclinical research efforts in Biogen’s Neurodegeneration Research Unit. He is responsible for developing and driving a diverse preclinical portfolio of programs, to complement Biogen’s development efforts for their a-synuclein antibody, which is in Phase 2 trials, using multiple modalities, from antibodies and antisense oligonucleotides, in collaboration in Ionis, to gene therapy and small molecules, targeting mechanisms strongly supported by human genetics and pathology, to deliver novel disease-modifying therapeutics to patients. Warren has 22 years of industry experience, working for GlaxoSmithKline, Wyeth, Pfizer and now Biogen.
